GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings (WGS) has reported Current Deferred Revenue for 3 consecutive years, with $40000.0 the latest figure, recorded in Q4 2022.

• On a quarterly basis, Current Deferred Revenue fell 91.54% year-over-year to $40000.0 in Q4 2022; TTM through Dec 2022 was $40000.0, a 91.54% decrease from a year earlier, with the FY2022 full-year figure at $40000.0, down 91.54% from the prior year.
• Current Deferred Revenue was $40000.0 for Q4 2022 at GeneDx Holdings, down from $2.8 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $3.8 million in Q1 2022 and troughed at $40000.0 in Q4 2022.
• A 3-year average of $2.1 million and a median of $2.8 million in 2021 frame the typical range for Current Deferred Revenue.
• The widest YoY moves for Current Deferred Revenue: up 472.82% in 2022, down 91.54% in 2022.
• Over 3 years, Current Deferred Revenue stood at $3.8 million in 2020, then plunged by 87.59% to $473000.0 in 2021, then plunged by 91.54% to $40000.0 in 2022.
• The last three Current Deferred Revenue figures came in at $40000.0 (Q4 2022), $2.8 million (Q3 2022), and $3.2 million (Q2 2022), per Business Quant data.